Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
pathophysiology
treatment
α-synuclein
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
18
10
2019
revised:
26
02
2020
accepted:
09
03
2020
pubmed:
16
4
2020
medline:
28
4
2021
entrez:
16
4
2020
Statut:
ppublish
Résumé
Multiple system atrophy (MSA) is a rare, untreatable neurodegenerative disorder characterized by accumulation of α-synuclein in oligodendroglial inclusions. As such, MSA is a synucleinopathy along with Parkinson's disease (PD) and dementia with Lewy bodies. Activation of the abelson tyrosine kinase c-Abl leads to phosphorylation of α-synuclein at tyrosine 39, thereby promoting its aggregation and subsequent neurodegeneration. The c-Abl inhibitor nilotinib used for the treatment of chronic myeloid leukemia based on data collected in preclinical models of PD might interfere with pathogenic mechanisms that are relevant to PD and dementia with Lewy bodies, which motivated its assessment in an open-label clinical trial in PD and dementia with Lewy bodies patients. The objective of this study was to assess the preclinical efficacy of nilotinib in the specific context of MSA. Mice expressing human wild-type α-synuclein in oligodendrocytes received daily injection of nilotinib (1 or 10 mg/kg) over 12 weeks. Postmortem analysis included the assessment of c-Abl activation, α-synuclein burden, and dopaminergic neurodegeneration. α-Synuclein phosphorylated at tyrosine 39 was detected in glial cytoplasmic inclusions in MSA patients. Increased activation of c-Abl and α-synuclein phosphorylation at tyrosine 39 were found in transgenic mice. Despite significant inhibition of c-Abl and associated reduction of α-synuclein phosphorylation at tyrosine 39 by 40%, nilotinib failed to reduce α-synuclein aggregate burden (including phosphorylation at serine 129) in the striatum and cortex or to lessen neurodegeneration in the substantia nigra. This preclinical study suggests that partial inhibition of c-Abl and reduction of α-synuclein phosphorylation at tyrosine 39 may not be a relevant target for MSA. © 2020 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Multiple system atrophy (MSA) is a rare, untreatable neurodegenerative disorder characterized by accumulation of α-synuclein in oligodendroglial inclusions. As such, MSA is a synucleinopathy along with Parkinson's disease (PD) and dementia with Lewy bodies. Activation of the abelson tyrosine kinase c-Abl leads to phosphorylation of α-synuclein at tyrosine 39, thereby promoting its aggregation and subsequent neurodegeneration. The c-Abl inhibitor nilotinib used for the treatment of chronic myeloid leukemia based on data collected in preclinical models of PD might interfere with pathogenic mechanisms that are relevant to PD and dementia with Lewy bodies, which motivated its assessment in an open-label clinical trial in PD and dementia with Lewy bodies patients. The objective of this study was to assess the preclinical efficacy of nilotinib in the specific context of MSA.
METHODS
Mice expressing human wild-type α-synuclein in oligodendrocytes received daily injection of nilotinib (1 or 10 mg/kg) over 12 weeks. Postmortem analysis included the assessment of c-Abl activation, α-synuclein burden, and dopaminergic neurodegeneration.
RESULTS
α-Synuclein phosphorylated at tyrosine 39 was detected in glial cytoplasmic inclusions in MSA patients. Increased activation of c-Abl and α-synuclein phosphorylation at tyrosine 39 were found in transgenic mice. Despite significant inhibition of c-Abl and associated reduction of α-synuclein phosphorylation at tyrosine 39 by 40%, nilotinib failed to reduce α-synuclein aggregate burden (including phosphorylation at serine 129) in the striatum and cortex or to lessen neurodegeneration in the substantia nigra.
CONCLUSIONS
This preclinical study suggests that partial inhibition of c-Abl and reduction of α-synuclein phosphorylation at tyrosine 39 may not be a relevant target for MSA. © 2020 International Parkinson and Movement Disorder Society.
Substances chimiques
Pyrimidines
0
alpha-Synuclein
0
nilotinib
F41401512X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1163-1172Informations de copyright
© 2020 International Parkinson and Movement Disorder Society.
Références
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71(9):670-676.
Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med 2015;372(3):249-263.
Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. The Lancet Neurol 2009;8(12):1172-1178.
Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004;5(1):33-44.
Imam SZ, Zhou Q, Yamamoto A, et al. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. J Neurosci 2011;31(1):157-163.
Ko HS, Lee Y, Shin J-HH, et al. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A 2010;107(38):16691-16696.
Derkinderen P, Scales TM, Hanger DP, et al. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci 2005;25(28):6584-6593.
Jing Z, Caltagarone J, Bowser R. Altered subcellular distribution of c-Abl in Alzheimer's disease. J Alzheimers Dis 2009;17(2):409-422.
Tremblay MA, Acker CM, Davies P. Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J Alzheimers Dis 2010;19(2):721-733.
Schlatterer SD, Acker CM, Davies P. c-Abl in neurodegenerative disease. J Mol Neurosci 2011;45(3):445-452.
Brahmachari S, Ge P, Lee S, et al. Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. J Clin Invest 2016;126(8):2970-2988.
Mahul-Mellier A-LL, Fauvet B, Gysbers A, et al. c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet 2014;23(11):2858-2879.
Hantschel O. Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer 2012;3(5-6):436-446.
Hebron ML, Lonskaya I, Moussa C. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. Hum Mol Genet 2013;22(16):3315-3328.
Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko H. The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Sci Rep 2014;4.
Imam SZ, Trickler W, Kimura S, et al. Neuroprotective efficacy of a new brain-penetrating C-Abl Inhibitor in a murine Parkinson's disease model. PLoS One 2013;8(5).
Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002;3(6):583-588.
Refolo V, Bez F, Polissidis A, et al. Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. Acta Neuropathol Commun 2018;6(1):2.
Del Bello F, Bonifazi A, Giorgioni G, et al. 1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1) as a model for the rational design of a novel class of brain penetrant ligands with high affinity and selectivity for dopamine D4 receptor. J Med Chem 2018;61(8):3712-3725.
Fernagut PO, Meissner WG, Biran M, et al. Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy. Synapse 2014;68(3):98-106.
Stefanova N, Reindl M, Neumann M, et al. Oxidative stress in transgenic mice with oligodendroglial α-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 2005;166(3):869-876.
Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010;1804(3):445-453.
Pagan FL, Hebron ML, Wilmarth B, et al. Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease. Pharmacol Res Perspect 2019;7(2):e00470.
Pagan F, Hebron M, Valadez EH, et al. Nilotinib effects in Parkinson's disease and dementia with Lewy bodies. J Parkinsons Dis 2016;6(3):503-517.
Lee S, Kim S, Park YJ, et al. The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model. Hum Mol Genet 2018;27(13):2344-2356.
Brahmachari S, Karuppagounder SS, Ge P, et al. c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential. J Parkinsons Dis 2017;7(4):589-601.
Burré J, Sharma M, Sudhof TC. Cell biology and pathophysiology of α-synuclein. Cold Spring HarbPerspect 2018;8(3).
Beyer K, Ariza A. Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol 2013;47(2):509-524.
Oueslati A. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? J Parkinsons Dis 2016;6(1):39-51.
Kleinknecht A, Popova B, Lázaro DF, et al. C-terminal tyrosine residue modifications modulate the protective phosphorylation of serine 129 of α-synuclein in a yeast model of Parkinson's disease. PLoS Genet 2016;12(6):e1006098.
Tenreiro S, Eckermann K, Outeiro TF. Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci 2014;7:42.
Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011;144(5):689-702.
Huang Y, Song YJ, Murphy K, et al. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathol 2008;116(6):639-646.
Jellinger KA. Multiple system atrophy: an oligodendroglioneural synucleinopathy. J Alzheimer's Dis 2018;62(3):1141-1179.
Dawson TM, Dawson VL. The role of parkin in familial and sporadic Parkinson's disease. Mov Disord 2010;25(Suppl 1[0 1]):S32-S39.
Krismer F, Jellinger KA, Scholz SW, et al. Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies. Parkinsonism Relat Disord 2014;20(8):793-799.
Mavroeidi P, Arvanitaki F, Karakitsou A-KK, et al. Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models. Acta Neuropathol 2019;138(3):415-441.
Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 2014;62(3):387-398.
Peng C, Gathagan RJ, Covell DJ, Medellin C, Nature S-A. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature 2018;557(7706):558-563.
Yamasaki TR, Holmes BB, Furman JL, et al. Parkinson's disease and multiple system atrophy have distinct alpha-synuclein seed characteristics. J Biol Chem 2019;294(3):1045-1058.